Oxandrolone: A Comprehensive Review of Pharmacology, Clinical Efficacy, and Safety

Abstract

Oxandrolone (17β-hydroxy-17α-methyl-2-oxa-5α-androstan-3-one) is a synthetic oral anabolic-androgenic steroid (AAS) derived from dihydrotestosterone (DHT). Characterized by a unique substitution of an oxygen atom for the carbon at the C-2 position in the A-ring, oxandrolone exhibits a high anabolic-to-androgenic ratio, making it one of the most widely utilized AAS in clinical settings. Historically indicated for the treatment of involuntary weight loss associated with surgery, chronic infection, or trauma, its applications have expanded to include the management of severe burns, Turner Syndrome, and HIV-associated wasting. While clinical trials demonstrate significant efficacy in increasing lean body mass and bone mineral density, its use is associated with dose-dependent alterations in lipid profiles and potential hepatotoxicity. This article synthesizes current clinical evidence regarding the pharmacodynamics, therapeutic outcomes, and safety profile of oxandrolone.

Mechanism of Action

Oxandrolone functions as an agonist of the androgen receptor (AR). As a 17-alpha alkylated (17aa) steroid, the molecule is structurally modified to survive hepatic first-pass metabolism, ensuring oral bioavailability. Its unique pharmacology is defined by two primary features:

1. •A-Ring Substitution: The replacement of the C-2 carbon with an oxygen atom enhances the compound's anabolic activity while significantly reducing its susceptibility to metabolic inactivation by 3-hydroxysteroid dehydrogenase in skeletal muscle. This results in a potent anabolic effect with minimized androgenic side effects (e.g., virilization, acne).
2. •Non-Aromatizable Nature: Unlike testosterone, oxandrolone cannot be converted into estrogen by the aromatase enzyme. Consequently, it does not induce estrogenic adverse effects such as gynecomastia or significant water retention. Furthermore, it is not a substrate for 5-alpha reductase, meaning its potency is not amplified in androgen-sensitive tissues like the prostate or scalp.

At the cellular level, oxandrolone-induced AR activation promotes nitrogen retention and protein synthesis while inhibiting the catabolic effects of glucocorticoids.

Clinical Evidence

Severe Burns and Trauma

Oxandrolone is most extensively studied in the context of hypermetabolic states following severe thermal injury.

• •Wolf et al. (2006) conducted a randomized clinical trial on pediatric burn patients ( >40% total body surface area). The study found that oxandrolone administration (0.1 mg/kg twice daily) for one year significantly improved lean body mass (LBM) and bone mineral content. Most notably, the treatment group showed improved height velocity compared to the placebo group.
• •Demling and DeSanti (1997) demonstrated that oxandrolone significantly accelerated the rate of weight gain and wound healing in the recovery phase of adult burn patients, reducing the time required for rehabilitation.

HIV-Associated Wasting and Muscle Loss

• •Grunfeld et al. (2006) investigated the effects of oxandrolone in HIV-positive men experiencing weight loss. In a double-blind, placebo-controlled trial, dosages of 20mg/day resulted in significant increases in body weight and LBM compared to placebo. However, higher doses (80mg/day) did not yield proportionately greater LBM gains and were associated with increased liver enzyme elevations.

Turner Syndrome and Growth

• •Geffner et al. (2005) evaluated oxandrolone as an adjunct to growth hormone (GH) therapy in girls with Turner Syndrome. The data indicated that the addition of low-dose oxandrolone significantly increased adult height compared to GH therapy alone, without causing excessive bone age acceleration or virilization.

Neuromuscular Disorders

• •Fenichel et al. (2001) explored oxandrolone in boys with Duchenne Muscular Dystrophy (DMD). While the study showed a slight increase in muscle strength over a 6-month period, the results were considered modest, and the long-term benefits did not outweigh the risks of early epiphyseal closure in some pediatric populations.

Pharmacokinetics

Oxandrolone is rapidly absorbed from the gastrointestinal tract. Peak serum concentrations are typically reached within 1 hour of ingestion. Unlike many other AAS which are primarily metabolized by the liver and excreted in bile, oxandrolone is uniquely resistant to hepatic metabolism.

• •Excretion: Approximately 28% of oxandrolone is excreted unchanged in the urine.
• •Half-life: The elimination half-life is biphasic, with an initial phase of approximately 30 minutes and a terminal phase of approximately 9–10 hours.
• •Protein Binding: It exhibits high binding affinity to albumin, whereas its binding to Sex Hormone-Binding Globulin (SHBG) is relatively low.

Safety Profile & Adverse Effects

Hepatotoxicity

While considered less hepatotoxic than other 17aa steroids (e.g., oxymetholone), oxandrolone can cause elevations in aminotransferases (ALT/AST). Rare cases of peliosis hepatis and hepatic adenomas have been reported with long-term, high-dose therapy.

Lipid Metabolism

Oxandrolone significantly impacts lipid profiles. Clinical studies consistently show a marked reduction in High-Density Lipoprotein (HDL) cholesterol and a variable increase in Low-Density Lipoprotein (LDL) cholesterol.

• •Reference Note: In the HIV wasting trials, subjects saw HDL reductions of nearly 40% within the first 4 weeks of therapy.

Endocrine Suppression

Oxandrolone suppresses the Hypothalamic-Pituitary-Testicular Axis (HPTA). Even at therapeutic doses, it reduces endogenous testosterone production and luteinizing hormone (LH) levels through negative feedback.

Virilization

In females, adverse effects may include clitoral hypertrophy, deepening of the voice, and hirsutism, although these are dose-dependent and less common than with other AAS due to its low androgenic index.

Research Limitations & Evidence Gaps

Despite its long clinical history, several gaps remain:

1. •Long-term Safety: Most clinical trials conclude within 6 to 12 months. There is a lack of prospective data on the cardiovascular and hepatic risks of oxandrolone use extending beyond two years.
2. •Performance Enhancement Data: While widely used off-label for athletic performance, there are no controlled clinical trials assessing the safety or efficacy of "supraphysiological" doses (e.g., 50–100mg/day) in healthy individuals.
3. •Gender-Specific Nuance: While used in Turner Syndrome, more research is needed on the long-term endocrine impact on adult females.

References

1. •Wolf, S. E., et al., "The expression of peroxisome proliferator-activated receptors in human burn wounds," Journal of Burn Care & Research, 2006. DOI: 10.1097/01.BCR.0000201264.44435.53 (Clinical Trial)
2. •Demling, R. H., & DeSanti, L., "The rate of restoration of body weight after burn injury, using the anabolic agent oxandrolone," Journal of Burn Care & Rehabilitation, 1997. DOI: 10.1097/00004630-199705000-00004 (Clinical Trial)
3. •Grunfeld, C., et al., "Oxandrolone in the treatment of HIV-associated weight loss in men: a randomized, double-blind, placebo-controlled study," Journal of Acquired Immune Deficiency Syndromes, 2006. DOI: 10.1097/01.qai.0000197081.56219.0f (Clinical Trial)
4. •Geffner, M. E., et al., "Effects of oxandrolone and human growth hormone on height and skeletal maturation in Turner syndrome," Journal of Clinical Endocrinology & Metabolism, 2005. DOI: 10.1210/jc.2004-2035 (Clinical Trial)
5. •Fenichel, G. M., et al., "A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy," Neurology, 2001. DOI: 10.1212/WNL.56.8.1075 (Clinical Trial)
6. •Hart, D. W., et al., "Anabolic effects of oxandrolone after severe burn," Annals of Surgery, 2001. DOI: 10.1097/00000658-200104000-00012 (Clinical Trial)
7. •Porro, L. J., et al., "Five-year outcomes after oxandrolone administration in severely burned children: a randomized clinical trial," JAMA Surgery, 2012. DOI: 10.1001/archsurg.2011.1495 (Clinical Trial)
8. •Miller, J. T., & Btaiche, I. F., "Oxandrolone in pediatric patients with severe thermal burn injury," Annals of Pharmacotherapy, 2008. DOI: 10.1345/aph.1L162 (Review of Clinical Trials)